-
(
ZhongW-ZWangQMaoW-M, et al
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol
2018; 19: 139–148.29174310)
ZhongW-ZWangQMaoW-M, et al
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol
2018; 19: 139–148.29174310
ZhongW-ZWangQMaoW-M, et al
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol
2018; 19: 139–148.29174310,
ZhongW-ZWangQMaoW-M, et al
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol
2018; 19: 139–148.29174310
-
(
SocinskiMAJotteRMCappuzzoF, et al
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med
2018; 378: 2288–2301.29863955)
SocinskiMAJotteRMCappuzzoF, et al
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med
2018; 378: 2288–2301.29863955
SocinskiMAJotteRMCappuzzoF, et al
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med
2018; 378: 2288–2301.29863955,
SocinskiMAJotteRMCappuzzoF, et al
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med
2018; 378: 2288–2301.29863955
-
(
WuYLTsuboiMHeJ, et al
Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med
2020; 383: 1711–1723.32955177)
WuYLTsuboiMHeJ, et al
Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med
2020; 383: 1711–1723.32955177
WuYLTsuboiMHeJ, et al
Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med
2020; 383: 1711–1723.32955177,
WuYLTsuboiMHeJ, et al
Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med
2020; 383: 1711–1723.32955177
-
J.
Soria,
Y.
Ohe,
J.
Vansteenkiste,
T.
Reungwetwattana,
B.
Chewaskulyong,
K.
Lee,
A.
Dechaphunkul,
F.
Imamura,
N.
Nogami,
T.
Kurata,
I.
Okamoto,
Caicun
Zhou,
B.
Cho,
Ying
Cheng,
E.
Cho,
P.
Voon,
D.
Planchard,
Wu‐Chou
Su,
J.
Gray,
S.
Lee,
R.
Hodge,
M.
Marotti,
Y.
Rukazenkov,
S.
Ramalingam
(2018)
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 378
-
Yi-long
Wu,
M.
Tsuboi,
Jie
He,
T.
John,
C.
Grohé,
M.
Majem,
J.
Goldman,
K.
Laktionov,
Sang-We
Kim,
T.
Kato,
H.
Vu,
Shun
Lu,
K.
Lee,
C.
Akewanlop,
Chong-Jen
Yu,
F.
Marinis,
L.
Bonanno,
M.
Dómine,
F.
Shepherd,
L.
Zeng,
R.
Hodge,
A.
Atasoy,
Y.
Rukazenkov,
R.
Herbst
(2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
The New England journal of medicine
-
W.
Zhong,
Qun
Wang,
W.
Mao,
Songtao
Xu,
Lin
Wu,
Yi
Shen,
Yongyu
Liu,
Chun
Chen,
Ying
Cheng,
Lin
Xu,
Jun
Wang,
K.
Fei,
Xiao-fei
Li,
Jian
Li,
Cheng
Huang,
Zhidong
Liu,
Shun
Xu,
Ke-Neng
Chen,
Shi-dong
Xu,
Lunxu
Liu,
P.
Yu,
Buhai
Wang,
Haining
Ma,
Hong-Hong
Yan,
Xue-Ning
Yang,
Qing
Zhou,
Yi-long
Wu
(2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
The Lancet. Oncology, 19 1
-
M.
Socinski,
R.
Jotte,
F.
Cappuzzo,
F.
Orlandi,
D.
Stroyakovskiy,
N.
Nogami,
D.
Rodríguez-Abreu,
D.
Moro-Sibilot,
C.
Thomas,
F.
Barlesi,
G.
Finley,
C.
Kelsch,
Anthony
Lee,
S.
Coleman,
Y.
Deng,
Yijing
Shen,
M.
Kowanetz,
A.
López-Chávez,
A.
Sandler,
M.
Reck
(2018)
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
The New England Journal of Medicine, 378
-
H.
Wakelee,
S.
Dahlberg,
S.
Keller,
W.
Tester,
D.
Gandara,
S.
Graziano,
A.
Adjei,
N.
Leighl,
S.
Aisner,
J.
Rothman,
J.
Patel,
M.
Sborov,
S.
Mcdermott,
R.
Perez-soler,
A.
Traynor,
C.
Butts,
T.
Evans,
A.
Shafqat,
A.
Chapman,
S.
Kasbari,
L.
Horn,
S.
Ramalingam,
J.
Schiller
(2017)
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
The Lancet. Oncology, 18
-
Qingyuan
Huang,
Hua
Zhang,
J.
Hai,
M.
Socinski,
E.
Lim,
Haiquan
Chen,
J.
Stebbing
(2017)
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
OncoImmunology, 7
-
A.
Rittmeyer,
F.
Barlesi,
D.
Waterkamp,
Keunchil
Park,
F.
Ciardiello,
J.
Pawel,
S.
Gadgeel,
T.
Hida,
D.
Kowalski,
M.
Dols,
D.
Cortinovis,
J.
Leach,
J.
Polikoff,
C.
Barrios,
F.
Kabbinavar,
O.
Frontera,
F.
Marinis,
H.
Turna,
Jong-Seok
Lee,
M.
Ballinger,
M.
Kowanetz,
P.
He,
Daniel
Chen,
A.
Sandler,
D.
Gandara
(2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet, 389
-
M.
Reck,
T.
Mok,
M.
Nishio,
R.
Jotte,
F.
Cappuzzo,
F.
Orlandi,
D.
Stroyakovskiy,
N.
Nogami,
D.
Rodríguez-Abreu,
D.
Moro-Sibilot,
C.
Thomas,
F.
Barlesi,
G.
Finley,
Anthony
Lee,
S.
Coleman,
Y.
Deng,
M.
Kowanetz,
G.
Shankar,
W.
Lin,
M.
Socinski
(2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
The Lancet. Respiratory medicine, 7 5
-
(
HuangACPostowMAOrlowskiRJ, et al
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature
2017; 545: 60–65.28397821)
HuangACPostowMAOrlowskiRJ, et al
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature
2017; 545: 60–65.28397821
HuangACPostowMAOrlowskiRJ, et al
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature
2017; 545: 60–65.28397821,
HuangACPostowMAOrlowskiRJ, et al
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature
2017; 545: 60–65.28397821
-
Alexander
Huang,
M.
Postow,
M.
Postow,
R.
Orlowski,
R.
Mick,
B.
Bengsch,
Sasikanth
Manne,
Wei
Xu,
S.
Harmon,
Josephine
Giles,
Brandon
Wenz,
Matthew
Adamow,
D.
Kuk,
K.
Panageas,
Cristina
Carrera,
Christina
Carrera,
P.
Wong,
Felix
Quagliarello,
B.
Wubbenhorst,
K.
D’Andrea,
Kristen
Pauken,
R.
Herati,
Ryan
Staupe,
J.
Schenkel,
S.
McGettigan,
S.
Kothari,
Sangeeth
George,
R.
Vonderheide,
R.
Amaravadi,
G.
Karakousis,
L.
Schuchter,
Xiaowei
Xu,
K.
Nathanson,
J.
Wolchok,
T.
Gangadhar,
E.
Wherry
(2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Nature, 545
-
(
ReckMMokTSKNishioM, et al
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med
2019; 7: 387–401.30922878)
ReckMMokTSKNishioM, et al
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med
2019; 7: 387–401.30922878
ReckMMokTSKNishioM, et al
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med
2019; 7: 387–401.30922878,
ReckMMokTSKNishioM, et al
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med
2019; 7: 387–401.30922878
-
(
KellyKAltorkiNKEberhardtWE, et al
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol
2015; 33: 4007–4014.26324372)
KellyKAltorkiNKEberhardtWE, et al
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol
2015; 33: 4007–4014.26324372
KellyKAltorkiNKEberhardtWE, et al
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol
2015; 33: 4007–4014.26324372,
KellyKAltorkiNKEberhardtWE, et al
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol
2015; 33: 4007–4014.26324372
-
(
WestHMcCleodMHusseinM, et al
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol
2019; 20: 924–937.31122901)
WestHMcCleodMHusseinM, et al
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol
2019; 20: 924–937.31122901
WestHMcCleodMHusseinM, et al
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol
2019; 20: 924–937.31122901,
WestHMcCleodMHusseinM, et al
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol
2019; 20: 924–937.31122901
-
(
WakeleeHADahlbergSEKellerSM, et al
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol
2017; 18: 1610–1623.29129443)
WakeleeHADahlbergSEKellerSM, et al
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol
2017; 18: 1610–1623.29129443
WakeleeHADahlbergSEKellerSM, et al
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol
2017; 18: 1610–1623.29129443,
WakeleeHADahlbergSEKellerSM, et al
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol
2017; 18: 1610–1623.29129443
-
H.
West,
M.
Mccleod,
M.
Hussein,
A.
Morabito,
A.
Rittmeyer,
H.
Conter,
H.
Kopp,
D.
Daniel,
S.
McCune,
T.
Mekhail,
A.
Zer,
N.
Reinmuth,
A.
Sadiq,
A.
Sandler,
W.
Lin,
T.
Lohmann,
V.
Archer,
Lijia
Wang,
M.
Kowanetz,
F.
Cappuzzo
(2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
The Lancet. Oncology
-
(
SoriaJCOheYVansteenkisteJ, et al
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med
2018; 378: 113–125.29151359)
SoriaJCOheYVansteenkisteJ, et al
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med
2018; 378: 113–125.29151359
SoriaJCOheYVansteenkisteJ, et al
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med
2018; 378: 113–125.29151359,
SoriaJCOheYVansteenkisteJ, et al
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med
2018; 378: 113–125.29151359
-
(
RittmeyerABarlesiFWaterkampD, et al
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet
2017; 389: 255–265.27979383)
RittmeyerABarlesiFWaterkampD, et al
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet
2017; 389: 255–265.27979383
RittmeyerABarlesiFWaterkampD, et al
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet
2017; 389: 255–265.27979383,
RittmeyerABarlesiFWaterkampD, et al
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet
2017; 389: 255–265.27979383
-
(
HuangQZhangHHaiJ, et al
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: a meta-analysis of randomized trials. Oncoimmunology
2018; 7: e1396403.30524878)
HuangQZhangHHaiJ, et al
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: a meta-analysis of randomized trials. Oncoimmunology
2018; 7: e1396403.30524878
HuangQZhangHHaiJ, et al
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: a meta-analysis of randomized trials. Oncoimmunology
2018; 7: e1396403.30524878,
HuangQZhangHHaiJ, et al
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: a meta-analysis of randomized trials. Oncoimmunology
2018; 7: e1396403.30524878
-
K.
Kelly,
N.
Altorki,
W.
Eberhardt,
M.
O'Brien,
D.
Spigel,
L.
Crinò,
C.
Tsai,
Joo‐Hang
Kim,
E.
Cho,
P.
Hoffman,
S.
Orlov,
P.
Serwatowski,
Jiuzhou
Wang,
M.
Foley,
J.
Horan,
F.
Shepherd
(2015)
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 34